As of close of business last night, Pliant Therapeutics Inc’s stock clocked out at $15.14, up 4.20% from its previous closing price of $14.53. In other words, the price has increased by $+0.61 from its previous closing price. On the day, 542864 shares were traded.
Ratios:
To gain a deeper understanding of PLRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.72 and its Current Ratio is at 17.72. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $41.
On May 18, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $48.
On April 13, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $44.Robert W. Baird initiated its Outperform rating on April 13, 2023, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 17 ’24 when Coulie Bernard sold 25,721 shares for $17.23 per share. The transaction valued at 443,173 led to the insider holds 316,382 shares of the business.
Lefebvre Eric sold 10,295 shares of PLRX for $177,383 on Jan 17 ’24. The Chief Medical Officer now owns 156,920 shares after completing the transaction at $17.23 per share. On Jan 17 ’24, another insider, Hull Hans, who serves as the Chief Business Officer of the company, sold 9,786 shares for $17.23 each. As a result, the insider received 168,613 and left with 185,069 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLRX now has a Market Capitalization of 913.83M and an Enterprise Value of 430.96M. For the stock, the TTM Price-to-Sale (P/S) ratio is 577.24 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 272.76 whereas that against EBITDA is -2.72.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $30.85, while it has fallen to a 52-week low of $12.60. The 50-Day Moving Average of the stock is 16.94, while the 200-Day Moving Average is calculated to be 17.10.
Shares Statistics:
It appears that PLRX traded 428.32K shares on average per day over the past three months and 336.97k shares per day over the past ten days. A total of 59.92M shares are outstanding, with a floating share count of 52.74M. Insiders hold about 12.44% of the company’s shares, while institutions hold 100.23% stake in the company. Shares short for PLRX as of Feb 29, 2024 were 6.86M with a Short Ratio of 16.02, compared to 6.21M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.39% and a Short% of Float of 11.60%.
Earnings Estimates
As of right now, 13 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.77 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$0.83, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.81, with high estimates of -$0.7 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.88 and -$3.6 for the fiscal current year, implying an average EPS of -$3.28. EPS for the following year is -$3.47, with 13 analysts recommending between -$2.66 and -$4.42.
